CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
APL-130277drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02228590
NCT02228590Phase 2Completed
CompareCT.gov

A Phase 2 Study to Examine the Safety, Tolerability and Efficacy of APL-130277 in Patients With Parkinson's Disease

Sumitomo Pharma America, Inc.·interventional·Posted Aug 29, 2014·Updated Jul 30, 2020

In Brief

A Phase 2 clinical trial evaluating APL-130277 for Parkinson's Disease. Completed, enrolled 20 participants across 4 sites.

Detailed Summary

The primary objective of this study is to evaluate the efficacy, tolerability and safety of single treatments of APL-130277 in 16 patients with Parkinson's Disease (PD)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 29, 2014
Enrollment StartAug 31, 2014
Primary CompletionNov 24, 2014
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 11.8 years ago

Interventions

APL-130277drug

Apomorphine Hydrochloride, Sublingual Thin Film